ENTPD1 and cancer: It has been widely demonstrated that CD39 and CD73 may be overexpressed in cancer cells, different immune cell subsets and stroma cells working in a coordinated way to arrest antitumor immunity via increasing levels of adenosine in the tumor microenvironment (TME) (Allard et al., 2017).